Manufacturing Cures: Infrastructure Challenges Facing Cell And Gene Therapy Developers

To Ensure Broad Patient Access To Cell And Gene Therapies Stakeholders Must Address Manufacturing Challenges

As more regenerative medicine products approach clinical testing and commercialization, stakeholders in the field are increasingly pressed to address substantial challenges, including pricing and reimbursement, GMP manufacturing, and clinical availability, and patient accessibility to these life changing therapies.

regenerative-medicine
The supply chain for managing new cell and gene therapies is incredibly complex • Source: Shutterstock

Over the past decade, advanced therapies have transitioned from academic dream to a clinical reality. With the recent approval of AveXis/Novartis AG’s Zolgensma, a gene therapy for spinal muscular atrophy (SMA) Type 1, and the international approvals of Novartis’ Kymriah, Kite Pharmaceuticals/Gilead Sciences Inc.’s Yescarta, and Spark Therapeutics Inc.'s Luxturna, it is clear that increasing numbers of patients will benefit from regenerative medicine therapies in the coming years.

Though this field has the potential to dramatically transform the health care landscape and treat patients who have in the...

More from Market Intelligence

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Pharma’s Dance With Trump Risks Distracting From Longer-Term Threats

 
• By 

Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.

Tackling Fraud In The UK: Pharma, Are You Ready?

 
• By 

UK pharma faces a critical turning point as the Economic Crime and Corporate Transparency Act introduces the "Failure to Prevent Fraud" offense in September 2025, requiring companies to transform their approach to fraud prevention or face severe consequences.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

More from In Vivo

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.